Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study (Q30407709)

24 September 2017

Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study (English)

1 reference

24 September 2017

1 reference

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Kimberly K Leslie

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

7

Vicky Makker

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Gini F Fleming

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Brandon Marzullo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Richard J Zaino

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Susan A Davidson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Michael Pearl

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

James J Burke

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Susan L Zweizig

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Linda Van Le

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Parviz Hanjani

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Gordon Downey

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Joan L Walker

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Henry D Reyes

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

English

0 references

publication date

20 January 2014

1 reference

24 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

132

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

585-592

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details

2 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

Molecular targets and targeted therapeutics in endometrial cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

A mechanism for synergy with combined mTOR and PI3 kinase inhibitors

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

One- and two-stage designs for stratified phase II clinical trials

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063288

Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group

26 November 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.015

Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.015

Confidence limits for probability of response in multistage phase II clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.015

A Survey of Exact Inference for Contingency Tables

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.015

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.015

Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.015

Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.015

Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.015

ACE inhibitors and pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.015

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.015

10.1016/J.YGYNO.2014.01.015

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24456823%20AND%20SRC:MED&resulttype=core&format=json